MNKD
MannKindANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
The supportive view is that MannKind entered 2026 with multiple concrete milestones: Q1 2026 total revenue of $90.2M was up 15% year over year, Afrezza pediatric approval has already been secured, Furoscix net sales were $15.5M in Q1, and the July 26, 2026 Furoscix ReadyFlow decision plus pulmonary pipeline milestones can broaden the company's revenue base if execution holds. [#SEC-8K-2026-05-06] [#8-K-2026-06-02]
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Afrezza pediatric approval is positive, but lack of early launch traction or slower-than-expected adoption would weaken the value of the recent label expansion. [#8-K-2026-06-02]
Momentum
66
Value
61
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.90 · Bull $6.40 · Bear $3.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.59
Why
Momentum66 · Δ7d +6.1
Value61 · Δ7d -0.1
Sentiment66 · Δ7d -11.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
66
26% active weight
Current posture
7d trendImproving
Δ7d
+6.1
Δ21d
+0.3
Value
61
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.1
Sentiment
66
34% active weight
Current posture
7d trendSoftening
Δ7d
-11.3
Δ21d
+8.8
Why this grade
Composite grade A. Momentum 66.5 / Value 61.3 / Sentiment 65.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.25B
Beta
0.84
Shares Out
308.95M
P/E (TTM)
60.7
P/S (TTM)
5.50
P/FCF (TTM)
39.77
Rev YoY
+15.1%
EPS YoY
-231.5%
Gross Margin
+73.3%
Op Margin
+18.8%
Net Debt
$302.04M
Current Ratio
1.87
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology